Patrick Hwu Selected Research

docosahexaenoyl-paclitaxel

12/2010	Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.
8/2009	Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrick Hwu Research Topics

Disease

185	Neoplasms (Cancer) 12/2022 - 01/2002
149	Melanoma (Melanoma, Malignant) 01/2022 - 01/2002
26	Neoplasm Metastasis (Metastasis) 11/2020 - 05/2002
14	Disease Progression 01/2020 - 01/2009
8	Uveal melanoma 01/2021 - 06/2010
8	Renal Cell Carcinoma (Grawitz Tumor) 01/2020 - 01/2002
8	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 05/2002
8	Brain Neoplasms (Brain Tumor) 12/2019 - 12/2010
6	Experimental Melanoma 01/2021 - 12/2003
6	Lung Neoplasms (Lung Cancer) 01/2018 - 01/2016
5	Inflammation (Inflammations) 01/2021 - 01/2009
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2018
4	Adenocarcinoma 10/2020 - 04/2012
3	Enterocolitis 01/2022 - 10/2018
3	Sarcoma (Soft Tissue Sarcoma) 01/2020 - 01/2017
3	Testicular Neoplasms (Testicular Cancer) 10/2019 - 01/2017
3	Diarrhea 10/2018 - 01/2002
3	Exanthema (Rash) 01/2018 - 10/2006
3	Fatigue 01/2018 - 01/2009
3	Kidney Neoplasms (Kidney Cancer) 08/2003 - 05/2002
2	Arthritis (Polyarthritis) 12/2022 - 12/2017
2	Colitis 01/2022 - 10/2018
2	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 01/2021
2	Bites and Stings (Sting) 01/2021 - 12/2015
2	T-Cell Lymphoma (Lymphoma, T Cell) 01/2020 - 03/2012
2	Colonic Neoplasms (Colon Cancer) 01/2020 - 12/2015

Drug/Important Bio-Agent (IBA)

48	AntigensIBA 01/2021 - 01/2002
28	Immune Checkpoint InhibitorsIBA 12/2022 - 03/2013
23	Interleukin-2 (IL2)IBA 01/2020 - 05/2002
21	Peptides (Polypeptides)IBA 01/2021 - 01/2002
19	Biomarkers (Surrogate Marker)IBA 12/2022 - 01/2012
18	Neoplasm Antigens (Tumor Antigens)IBA 10/2012 - 05/2002
16	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2002
16	VaccinesIBA 01/2022 - 05/2002
15	IpilimumabIBA 01/2022 - 11/2012
12	CytokinesIBA 01/2022 - 05/2002
11	AntibodiesIBA 12/2020 - 01/2011
10	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 02/2013
10	LigandsIBA 01/2022 - 12/2010
9	RNA (Ribonucleic Acid)IBA 01/2022 - 09/2012
8	Pharmaceutical PreparationsIBA 01/2021 - 08/2011
8	InterferonsIBA 01/2021 - 02/2011
8	VemurafenibIBA 01/2019 - 10/2012
7	pembrolizumabIBA 01/2021 - 01/2016
7	dabrafenibIBA 01/2021 - 04/2012
7	trametinibIBA 01/2021 - 02/2013
7	EpitopesIBA 12/2020 - 06/2003
7	Dacarbazine (DIC)FDA LinkGeneric 01/2018 - 08/2009
7	DNA (Deoxyribonucleic Acid)IBA 02/2016 - 05/2003
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 07/2003
6	NivolumabIBA 01/2021 - 04/2016
6	Monoclonal AntibodiesIBA 12/2020 - 06/2010
6	ChemokinesIBA 01/2018 - 11/2002
6	Temozolomide (Temodar)FDA LinkGeneric 10/2017 - 06/2009
6	Cancer VaccinesIBA 05/2013 - 01/2002
5	Chimeric Antigen ReceptorsIBA 01/2021 - 03/2012
5	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020 - 09/2004
5	HLA-A*02:01 antigenIBA 01/2017 - 08/2003
5	Differentiation AntigensIBA 01/2017 - 10/2002
5	Cisplatin (Platino)FDA LinkGeneric 08/2014 - 06/2009
4	CTLA-4 AntigenIBA 01/2022 - 07/2003
4	Messenger RNA (mRNA)IBA 01/2022 - 01/2017
4	Monophenol Monooxygenase (Tyrosinase)IBA 01/2021 - 01/2002
4	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2019 - 10/2012
4	Paclitaxel (Taxol)FDA LinkGeneric 11/2017 - 08/2009
3	atezolizumabIBA 11/2021 - 01/2018
3	Interleukin-12 (IL 12)IBA 01/2021 - 01/2017
3	Interleukin-1 (Interleukin 1)IBA 01/2021 - 10/2012
3	Protein Subunit VaccinesIBA 01/2021 - 06/2011
3	incomplete Freund's adjuvantIBA 01/2021 - 06/2011
3	monomethyl auristatin EIBA 12/2020 - 06/2010
3	Glycoproteins (Glycoprotein)IBA 12/2020 - 06/2010
3	HLA-A Antigens (HLA-A)IBA 10/2020 - 01/2017
3	bempegaldesleukinIBA 01/2020 - 01/2019
3	Biological ProductsIBA 09/2019 - 04/2011
3	InterleukinsIBA 12/2017 - 08/2003
3	SurvivinIBA 08/2017 - 11/2007
3	Dasatinib (BMS 354825)FDA Link 02/2013 - 08/2009
3	Sorafenib (BAY 43-9006)FDA Link 02/2012 - 12/2008
3	interleukin-21 (interleukin 21)IBA 10/2007 - 12/2003
2	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2016
2	MicroRNAs (MicroRNA)IBA 01/2022 - 03/2015
2	Bevacizumab (Avastin)FDA Link 11/2021 - 07/2003
2	Toll-Like Receptor 9IBA 01/2021 - 04/2011
2	CD40 Ligand (CD40L)IBA 01/2021 - 01/2002
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 04/2011
2	Immunoconjugates (Immunoconjugate)IBA 12/2020 - 11/2014
2	Recombinant ProteinsIBA 11/2020 - 11/2002
2	Indicators and Reagents (Reagents)IBA 08/2020 - 09/2019
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2019 - 08/2012
2	Immunoglobulins (Immunoglobulin)IBA 09/2019 - 11/2014
2	Infliximab (Remicade)FDA Link 04/2019 - 10/2018

Therapy/Procedure

129	Therapeutics 12/2022 - 05/2002
86	Immunotherapy 01/2022 - 05/2002
20	Drug Therapy (Chemotherapy) 11/2021 - 05/2002
14	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022 - 01/2011
5	Radiotherapy 01/2020 - 12/2004
4	Precision Medicine 01/2021 - 01/2016
3	Lymph Node Excision (Lymph Node Dissection) 11/2014 - 01/2006
2	Injections 01/2021 - 01/2020